New RVX research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute. If the link doesn't work, go to: http://www.leeuwenhoeck.com/ and you'll see the link to the latest research report. Here's the summary:

"Resverlogix (RVX.TO) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. In October 2015, Resverlogix initiated a Phase III trial ‘BETonMACE’ with apabetalone (RVX-208). The main objective of the Phase III BETonMACE trial will be to confirm MACE reduction in high risk cardiovascular disease patients with type 2 diabetes and low HDL. Based on our adjusted NPV valuation, we believe Resverlogix is substantially undervalued at the current share price of CAD 1.42. We have increased our valuation of Resverlogix to CAD 8.50 from CAD 5.85 per share."